Role of Paediatric DTG in Improving HIV Care for Children

Dolutegravir (DTG) is the World Health Organisation’s (WHO) recommended first-line drug to treat HIV because it is more effective, easier to take, has fewer side effects than alternatives, and has a high genetic barrier to developing drug resistance. A long-awaited formulation designed specifically for children is now available in low-and middle-income countries including South Africa. Join this webinar and learn more about integrating  paediatric DTG in clinical practice. 2 CPD point is allocated.